Biohaven

Biohaven Equity Growth

The Year-over-Year Equity Growth of Biohaven (BHVN) as of Nov 4, 2026 is -87.70 %. In the previous year, Year-over-Year Equity Growth was -1.06 % — a change of 8,169.33% (lower).

Equity Growth

-87.70 %

YoY

8,169.33%

Last updated:

Year-over-Year Equity Growth of Biohaven is 2025 -87.70 % . Year-over-Year Equity Growth of Biohaven was 2024 -1.06 % . It decreases by 8,169.33% lower compared to the previous year.

The Biohaven Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
14.36 USD
Jan 1, 2019
-104.92 USD
Jan 1, 2020
1,134.23 USD
Jan 1, 2021
23.33 USD
Jan 1, 2022
468.98 USD
Jan 1, 2023
-20.56 USD
Jan 1, 2024
-1.06 USD
Jan 1, 2025
-87.70 USD
The Biohaven Equity Growth history
YEAREquity GrowthYoY
-87.70 %+8,169.33%
-1.06 %-94.84%
-20.56 %-104.38%
468.98 %+1,910.53%
23.33 %-97.94%
1,134.23 %-1,181.05%
-104.92 %-830.71%
14.36 %-99.81%
7,431.72 %-2,918.93%
-263.64 %+743.64%
-31.25 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biohaven Stock analysis

What does Biohaven do? Biohaven Pharmaceutical Holding Co. Ltd. generates revenue through the research and development of late-stage product candidates targeting neurological diseases and rare disorders. The company utilizes its glutamate platform to advance clinical-stage compounds for various indications, including trigriluzole for obsessive-compulsive disorder, spinocerebellar ataxia, and Alzheimer's disease. Additionally, the firm develops BHV-0223 for amyotrophic lateral sclerosis and BHV-5000 for conditions such as Rett syndrome, neuropathic pain, and treatment-resistant depression. The business model focuses on identifying and developing clinical-stage compounds that target orphan neurologic indications and other neurological pathways, with the company currently employing 825 full-time employees in New Haven, Connecticut. Biohaven is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biohaven stock

Year-over-Year Equity Growth of Biohaven is -87.70 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Biohaven since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Biohaven historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Biohaven

All Key Metrics — Biohaven